Navidea Biopharmaceuticals, Inc. (NAVB) financial statements (2021 and earlier)

Company profile

Business Address 4995 BRADENTON AVENUE
DUBLIN, OH 43017
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3135275
Cash and cash equivalents3133275
Short-term investments   2   
Inventory, net of allowances, customer advances and progress billings0  (0)111
Inventory0  (0)111
Prepaid expense    0  
Other undisclosed current assets4229752
Total current assets:7361411139
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment0000123
Intangible assets, net (including goodwill)1000000
Intangible assets, net (excluding goodwill)1000000
Deferred costs      0
Other noncurrent assets0111000
Other undisclosed noncurrent assets   5  0
Total noncurrent assets:1117223
TOTAL ASSETS:84721121512
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2222833
Accounts payable1101721
Accrued liabilities0000000
Employee-related liabilities1121111
Debt11025204
Restructuring reserve      0
Estimated litigation liability   3   
Disposal group, including discontinued operation   0   
Deferred revenue and credits 21 
Other undisclosed current liabilities2111722
Total current liabilities:54387069
Noncurrent Liabilities
Long-term debt and lease obligation01  106130
Long-term debt, excluding current maturities    106130
Operating lease, liability01
Liabilities, other than long-term debt1100123
Deferred revenue and credits 00 
Deferred revenue11
Other liabilities  00123
Other undisclosed noncurrent liabilities  11   
Total noncurrent liabilities:1111106333
Total liabilities:6559806942
Stockholders' equity
Stockholders' equity attributable to parent, including:1(2)211(68)(54)(30)
Preferred stock      0
Preferred stock, shares subscribed but unissued, subscriptions receivable(10)      
Common stock0000000
Common stock, share subscribed but unissued, subscriptions receivable(5)      
Common stock, value, subscriptions00     
Additional paid in capital375346338331327326323
Accumulated other comprehensive loss  (0)(0)   
Accumulated deficit(359)(348)(337)(320)(395)(381)(353)
Other undisclosed stockholders' equity attributable to parent0      
Stockholders' equity attributable to noncontrolling interest111100 
Total stockholders' equity:2(1)212(68)(54)(30)
TOTAL LIABILITIES AND EQUITY:84721121512

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues111222136
Revenue, net019114
Sublease income 0
Cost of revenue(0)(0)(0)(0)(2)(2)(2)
Cost of goods and services sold   (0)(2)(2)(2)
Other undisclosed gross profit      1
Gross profit:111220115
Operating expenses(12)(12)(12)(16)(22)(30)(32)
Operating loss:(11)(11)(11)(14)(2)(19)(28)
Nonoperating income (expense)(0)00(0)(0)0(8)
Investment income, nonoperating00  (0) 0
Other nonoperating income (expense)(0)(0)0(0)(0)00
Interest and debt expense(0)(0)(5)(4)(2)(2)(6)
Loss from continuing operations before equity method investments, income taxes:(11)(11)(16)(18)(4)(21)(42)
Loss from equity method investments    (0)(0)(1)
Other undisclosed income (loss) from continuing operations before income taxes00(0)0(10)(7) 
Loss from continuing operations before income taxes:(11)(11)(16)(18)(14)(29)(43)
Income tax expense (benefit) (0)04 0 
Loss from continuing operations:(11)(11)(16)(14)(14)(28)(43)
Income (loss) from discontinued operations (0)   1 
Loss before gain (loss) on sale of properties:(11)(11)(16)(14)(14)(28)(43)
Other undisclosed net income  089   
Net income (loss):(11)(11)(16)75(14)(28)(43)
Net income attributable to noncontrolling interest 00000 
Other undisclosed net income (loss) attributable to parent    (0) 7
Net income (loss) attributable to parent:(11)(11)(16)75(14)(28)(36)
Preferred stock dividends and other adjustments(1)    (0) 
Other undisclosed net income available to common stockholders, basic    0  
Net income (loss) available to common stockholders, diluted:(11)(11)(16)75(14)(28)(36)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(11)(11)(16)75(14)(28)(43)
Other undisclosed comprehensive income (loss) 00(0)   
Comprehensive income (loss):(11)(11)(16)75(14)(28)(43)
Comprehensive income, net of tax, attributable to noncontrolling interest 00000 
Comprehensive income (loss), net of tax, attributable to parent:(11)(11)(16)75(14)(28)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: